JSMWH-WHS — JAPANESE WOMEN'S-HEALTH
SPECIALIST CERTIFICATION EXAMINATION,
INCLUDING MENOPAUSE/MIDLIFE WOMEN'S
HEALTH LATEST UPDATED 2026-2027 ACTUAL FINAL
PRACTICE EXAM WITH ALL POSSIBLE MOST
TESTED 100 PRACTICE QUESTIONS AND 100%
CORRECT VERIFIED ANSWERS WITH DETAILED
RATIONALES PLUS CERTIFIED ANSWER KEY
RATED A+ MOST RECENT!!!
1. A 52-year-old woman reports that her menstrual
cycles have become variable, with the length of her
cycles changing by 7 days or more from her
baseline. She still has periods. According to the
STRAW staging criteria, which stage best describes
her?
A. Late perimenopause
B. Early perimenopause
,C. Postmenopause
D. Premenopause
Correct Answer: B
Rationale: Early perimenopause is defined by
persistent variability in cycle length of seven days or
more, while menses continue. Late perimenopause
is characterized by skipped cycles and an interval of
60 days or more of amenorrhea.
2. A 49-year-old woman with a history of migraine
with aura is considering Menopause Hormone
Therapy (MHT) for severe hot flashes. Which
formulation is generally preferred to minimize
stroke risk?
A. Oral conjugated equine estrogens
B. Transdermal low-dose estradiol
C. Oral micronized progesterone only
D. Compounded bioidentical hormone cream
Correct Answer: B
Rationale: In women with migraine with aura,
transdermal low-dose estradiol is generally
,preferred over oral estrogens, as it avoids the first-
pass hepatic effect and is associated with a lower
risk of thromboembolic events and stroke .
3. A breast cancer survivor on an aromatase
inhibitor reports severe dyspareunia unresponsive to
lubricants and moisturizers. What is the most
appropriate next step?
A. Immediately discontinue the aromatase inhibitor
B. Prescribe systemic estrogen therapy without
oncology consultation
C. Recommend no further treatment is possible
D. Refer to oncology for shared decision-making
regarding low-dose vaginal estrogen
Correct Answer: D
Rationale: In breast cancer survivors, especially
those on aromatase inhibitors, decisions about
vaginal estrogen require shared decision-making
with oncology due to theoretical concerns about
systemic absorption affecting cancer recurrence
risk .
, 4. Which of the following is considered a benefit,
rather than a risk, of systemic Menopause Hormone
Therapy (MHT)?
A. Increased risk of gallbladder disease
B. Reduction in vasomotor symptoms and improved
bone mineral density
C. Increased risk of stroke in older women
D. Increased risk of breast cancer with long-term
combined use
Correct Answer: B
Rationale: Systemic hormone therapy is well
established as effective for reducing vasomotor
symptoms and preserving bone mineral density,
representing key clinical benefits weighed against
potential risks .
5. What is the recommended daily calcium intake
for most postmenopausal women to support bone
health?
SPECIALIST CERTIFICATION EXAMINATION,
INCLUDING MENOPAUSE/MIDLIFE WOMEN'S
HEALTH LATEST UPDATED 2026-2027 ACTUAL FINAL
PRACTICE EXAM WITH ALL POSSIBLE MOST
TESTED 100 PRACTICE QUESTIONS AND 100%
CORRECT VERIFIED ANSWERS WITH DETAILED
RATIONALES PLUS CERTIFIED ANSWER KEY
RATED A+ MOST RECENT!!!
1. A 52-year-old woman reports that her menstrual
cycles have become variable, with the length of her
cycles changing by 7 days or more from her
baseline. She still has periods. According to the
STRAW staging criteria, which stage best describes
her?
A. Late perimenopause
B. Early perimenopause
,C. Postmenopause
D. Premenopause
Correct Answer: B
Rationale: Early perimenopause is defined by
persistent variability in cycle length of seven days or
more, while menses continue. Late perimenopause
is characterized by skipped cycles and an interval of
60 days or more of amenorrhea.
2. A 49-year-old woman with a history of migraine
with aura is considering Menopause Hormone
Therapy (MHT) for severe hot flashes. Which
formulation is generally preferred to minimize
stroke risk?
A. Oral conjugated equine estrogens
B. Transdermal low-dose estradiol
C. Oral micronized progesterone only
D. Compounded bioidentical hormone cream
Correct Answer: B
Rationale: In women with migraine with aura,
transdermal low-dose estradiol is generally
,preferred over oral estrogens, as it avoids the first-
pass hepatic effect and is associated with a lower
risk of thromboembolic events and stroke .
3. A breast cancer survivor on an aromatase
inhibitor reports severe dyspareunia unresponsive to
lubricants and moisturizers. What is the most
appropriate next step?
A. Immediately discontinue the aromatase inhibitor
B. Prescribe systemic estrogen therapy without
oncology consultation
C. Recommend no further treatment is possible
D. Refer to oncology for shared decision-making
regarding low-dose vaginal estrogen
Correct Answer: D
Rationale: In breast cancer survivors, especially
those on aromatase inhibitors, decisions about
vaginal estrogen require shared decision-making
with oncology due to theoretical concerns about
systemic absorption affecting cancer recurrence
risk .
, 4. Which of the following is considered a benefit,
rather than a risk, of systemic Menopause Hormone
Therapy (MHT)?
A. Increased risk of gallbladder disease
B. Reduction in vasomotor symptoms and improved
bone mineral density
C. Increased risk of stroke in older women
D. Increased risk of breast cancer with long-term
combined use
Correct Answer: B
Rationale: Systemic hormone therapy is well
established as effective for reducing vasomotor
symptoms and preserving bone mineral density,
representing key clinical benefits weighed against
potential risks .
5. What is the recommended daily calcium intake
for most postmenopausal women to support bone
health?
